市場調査レポート

商品コード

1566146

乳がん治療薬の市場規模、シェア、成長分析、療法別、がんタイプ別、流通チャネル別、地域別 - 産業予測、2024年～2031年

Breast Cancer Therapeutics Market Size, Share, Growth Analysis, By Therapy, By Cancer Type, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日: 2024年10月06日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

乳がん治療薬の市場規模は2022年に312億2,000万米ドルと評価され、2023年の353億米ドルから2031年には945億3,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは13.1％で成長する見通しです。

現在、世界の乳がん治療薬市場は、乳がん罹患率の上昇や早期発見・治療の重要性に対する意識の高まりなど、さまざまな要因が重なり、力強い成長を遂げています。医療技術の革新と新規治療法の出現が市場拡大をさらに後押ししています。注目すべき動向は、個別化医療や標的療法へのシフトであり、HER2標的療法やホルモン療法の使用増加に代表されるように、患者の転帰や生存率を著しく向上させています。免疫療法や併用療法の開発も進展しており、有効性を向上させた治療の新たな道を提示しています。さらに、研究開発への多額の投資、製薬企業と研究機関の戦略的提携とともに、政府の支援策が市場の成長を活性化しています。しかし、治療費の高騰、副作用の可能性、地域によってはヘルスケアへのアクセスが限られているなどの課題も残っており、市場全体の進展を妨げる可能性があります。このような障害にもかかわらず、乳がん治療薬市場は、治療手段の進歩、社会的認知度の向上、医療政策の促進によって活況を呈しており、患者の予後改善と罹患者のQOL向上に対する楽観的な見方を植え付けています。特筆すべきは、米国の乳がん治療薬市場は、継続的な成長の可能性を反映し、次の予測期間においても持続的なCAGRを維持すると予測されていることです。

市場概要
標的療法
- アベマシクリブ
- アドトラスツズマブエムタンシン
- エベロリムス
- トラスツズマブ
- リボシクリブ
- パルボシクリブ
- ペルツズマブ
- オラパリブ
- その他
ホルモン療法
- 選択的エストロゲン受容体モジュレーター（SERM）
- アロマターゼ阻害剤
- エストロゲン受容体ダウンレギュレーター（ERD）
化学療法
免疫療法

乳がん治療薬市場：がんタイプ別

市場概要
ホルモン受容体
HER2+

乳がん治療薬市場：流通チャネル別

市場概要
病院薬局
小売薬局
オンライン薬局
その他

乳がん治療薬市場規模：地域別

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

Genentech（F. Hoffmann-La Roche Ltd）
Eli Lilly and Company
Novartis AG
AstraZeneca
Pfizer Inc.
Sanofi
Eisai Co. Ltd.
Kyowa Kirin
Bristol Myers Squibb（Celgene Corporation）
Merck & Co., Inc.
Johnson & Johnson
AbbVie Inc.
Gilead Sciences
Takeda Pharmaceutical Company Limited
Amgen Inc.
Teva Pharmaceutical Industries Ltd.
Daiichi Sankyo Company, Limited
Otsuka Pharmaceutical Co., Ltd.
Ipsen

Product Code: SQMIG35G2183

Breast Cancer Therapeutics Market size was valued at USD 31.22 billion in 2022 and is poised to grow from USD 35.30 billion in 2023 to USD 94.53 billion by 2031, growing at a CAGR of 13.1% in the forecast period (2024-2031).

The global breast cancer therapeutics market is currently witnessing robust growth, fueled by a confluence of factors that include the rising incidence of breast cancer and heightened awareness surrounding the importance of early detection and treatment. Innovations in medical technology and the emergence of novel therapies have further propelled market expansion. A notable trend is the shift towards personalized medicine and targeted therapies, exemplified by the increased use of HER2-targeted therapies and hormone therapies, which have significantly enhanced patient outcomes and survival rates. The development of immunotherapies and combination therapies is also making strides, presenting new avenues for treatment with improved efficacy. Furthermore, supportive government initiatives, along with substantial investments in research and development, and strategic collaborations between pharmaceutical firms and research institutions, are invigorating market growth. However, challenges persist, including the high costs of treatment, potential side effects, and limited healthcare access in certain regions, which could hinder overall market progress. Despite these obstacles, the breast cancer therapeutics market remains buoyed by advancements in treatment avenues, increased public awareness, and conducive healthcare policies, instilling optimism for better patient outcomes and quality of life for those affected by the disease. Notably, the US breast cancer therapeutics market is projected to maintain a sustainable compound annual growth rate (CAGR) over the next forecast period, reflecting continued growth potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Breast Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Breast Cancer Therapeutics Market Segmental Analysis

Global Breast Cancer Therapeutics Market is segmented by Therapy, Cancer Type, Distribution Channel, and region. Based on Therapy, the market is segmented into Targeted Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Everolimus, Trastuzumab, Ribociclib, Palbociclib, Pertuzumab, Olaparib, Others), Hormonal Therapy (Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Downregulators (ERDs)), Chemotherapy, and Immunotherapy. Based on Cancer Type, the market is segmented into Hormone Receptor, HER2+. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Breast Cancer Therapeutics Market

A significant market driver for the global breast cancer therapeutics market is the escalating prevalence of breast cancer, which continues to rise worldwide due to various factors, including lifestyle changes and genetic predispositions. This alarming increase has spurred heightened awareness and the implementation of early detection programs, fostering a robust demand for innovative and effective treatment options. Furthermore, advancements in diagnostic techniques and the emergence of personalized medicine have paved the way for the development of targeted therapies, significantly enhancing patient outcomes. As a result, there is an urgent need for novel therapeutics, driving investment and research in this vital market segment.

Restraints in the Breast Cancer Therapeutics Market

The global breast cancer therapeutics market faces a significant restraint due to the high cost of treatment, which can limit patient access to effective therapies. Innovative drugs often come with steep price tags, compounded by the need for prolonged treatment regimens and supportive care, placing substantial financial burdens on patients and healthcare systems alike. Limited insurance coverage and restricted access to affordable treatment options further exacerbate this issue, creating barriers to necessary care. Moreover, the protracted and demanding processes involved in drug development and regulatory approval can hinder the timely introduction of new therapies, restricting options for patients in need.

Market Trends of the Breast Cancer Therapeutics Market

The Breast Cancer Therapeutics market is witnessing a significant trend toward personalized medicine and targeted therapies, driven by groundbreaking advancements in genomic research and molecular diagnostics. As the understanding of breast cancer's genetic and molecular characteristics deepens, the development of tailored therapies has emerged, allowing for treatments that are finely tuned to the individual patient's cancer profile. This shift not only enhances the efficacy of therapeutic interventions but also minimizes side effects, leading to improved patient outcomes. Consequently, the market is poised for continued growth, as healthcare providers increasingly adopt these innovative approaches to elevate cancer care in breast cancer patients.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Regulatory Analysis
Pricing Analysis
Value Chain Analysis
Patent Analysis
Customer & Buying Criteria Analysis
Trade Analysis

Breast Cancer Therapeutics Market, By Therapy

Market Overview
Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
Immunotherapy

Breast Cancer Therapeutics Market, By Cancer Type

Market Overview
Hormone Receptor
HER2+

Breast Cancer Therapeutics Market, By Distribution Channel

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Breast Cancer Therapeutics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Genentech (F. Hoffmann-La Roche Ltd)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyowa Kirin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (Celgene Corporation)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments